Epigenetic Changes in Aging and Age-related Disease

David A Rowbotham¹, Erin A Marshall, Emily A Vucic, Jennifer Y Kennett, Wan L Lam and Victor D Martinez
BC Cancer Research Centre, Vancouver, BC, Canada

¹Corresponding author: David Rowbotham, BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC, Canada V5Z 1L3 Tel: +16046758111; Fax: +16046758232; Email: drowbotham@bccrc.ca

Rec date: Sep 05, 2014; Acc date: Oct 21, 2014; Pub date: Nov 04, 2014

Copyright: © 2014 Rowbotham DA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The epigenome refers to the complete set of heritable chemical modifications made to DNA and histone proteins. Certainly, the most well characterized epigenetic mark is the covalent addition of a methyl group to a CpG dinucleotide site in the genome. The DNA methylome—a collection of methyl marks established during embryogenesis—creates a complex regulatory network involved in cell type differentiation, homeostasis and regulating gene expression in response to environmental stimuli and stress throughout life. Collectively, an increasing body of research supports the notion that over time, diverging methylomes may account for substantial phenotypic discordance in monozygotic-twins and explain disparate susceptibilities to age-related disease. We review this evidence and discuss how a greater insight into the mechanisms of age-related epigenetic dysregulation may inform strategies for molecular diagnostics and therapeutic intervention.

Keywords: Methylome; Epigenome; Age-related disease; Epigenetic drift; CpG island; Methylome wide association study (MWAS); Monzygotic twins (MZ); Hutchinson-Gilford progeria syndrome (HGPS); Alzheimers disease (AD); Rheumatoid arthritis (RA); Type-2 diabetes (TD2); Stem cell exhaustion; Histone deacetylase (HDAC); Reactive oxygen species (ROS).

Introduction

The term epigenetics first arose to describe heritable changes in gene expression that did not involve changes to the base pair coding sequence of DNA, and to explain, in part, how cells with an identical genetic make-up can give rise to completely different tissue types [1]. A central effect involved in this process is DNA methylation, established by the covalent addition of a methyl group to cytosine residues in the context of cytosine-guanine di-nucleotides (so called “CpG sites”) by DNA methyltransferase (DNMT) enzymes [2,3]. CpG sites are often not in isolation: rather, they are embedded in the genome as discrete clusters of CpG sites (termed CpG islands) that range in size from 0.5 to 2 kilobases and are frequently located in the 5’ adjacent regions of transcriptional start sites [3]. With the advent of improved genome-wide methods to interrogate the methylome, discrete functional CpG sequences are continually being defined, for example CpG sites adjacent (within 2 kb) to CpG islands called “CpG islands shores”, which are closely associated with somatically imprinted, tissue-specific methylation patterns [4].

More than half of the genes in the genome contain CpG islands within their promoter and these islands are usually unmethylated in normal cells [3,5]. Methylation of CpG islands, however, can be detected at small subgroups of autosomal genes (<10%) in a tissue-specific manner. The functional role of CpG island [6] and CpG sites is context and loci specific and has been reviewed recently by Jones et al [7].

The establishment of the neonate methyleome during embryogenesis is critical to development. Shortly after fertilization, the paternal and maternal genomes combine in the same cell and DNA methylation patterns are nearly completely erased [8-10]. Remarkably, select genes remain “imprinted” with methyl marks corresponding to the parent of origin and these imprinted genes are often maintained throughout the life of the offspring [10]. Genomic imprinting results in the restriction of gene expression to either the maternal or paternal allele [11].

Figure 1: (A) Epigenetic maintenance of methylation at CpG dinucleotides. (A) Schematic illustration of the classical maintenance model for the propagation DNA methylation marks. After each round of replication, DNA is in a hemi-methylated state, with the daughter strand bearing nascent unmethylated CpG sites and the parent harboring the original CpG methylation status. Hemi-methylated DNA may undergo passive demethylation with another round of replication diluting out remaining methyl-CpG sites or hemi-methylated DNA can be restored to its original methylation state through the activity of DNA methyltransferase 1 (DNMT1) maintenance enzymes. Ten–eleven translocation methlycytosine dioxygenases (TET) enzymes actively demethylate DNA.

Methylation marks are established throughout embryological development by de novo methyltransferases DNMT3a and DNMT3b [12]. Until recently, it was thought that as lineage specificity is established, DNMT3 enzymes were shut off and DNMT1 was expressed in order to maintain tissue specific methylation patterns in differentiated cells. However, there is increasing evidence that...
DNMT3a is active in regulating gene expression in adult somatic cells, for example in mature neurons related to learning and memory [13,14]. The hypothesized first step in active cytosine demethylation is thought to be mediated by the recently discovered TET enzymes (ten-eleven translocation methylcytosine dioxygenases), which are able to catalyze the conversion of 5-methylcytosine (5mc) to 5-hydroxymethylcytosine (5hmC) [15,16]. Together, active methylation and demethylation events offer a model for the dynamic regulation of the genome (Figure 1A).

In combination with covalent modifications to histone (chromatin proteins) tails, somatic heritability of DNA methylation marks established during development leads to the persistence of highly tissue and cell type specific patterns of methylation [4,17-19]. For example, hypo methylation of the SRY (Sex-determining region on the Y chromosome) gene, encoding the master regulator of testis differentiation, results in transcriptional initiation of this gene exclusively in the gonads. In other tissue types, SRY is hyper methylated at the promoter region [20]. Additionally, differential methylation seems to be a critical mechanism involved in tissue reprogramming during the establishment of induced pluripotent stem cells (iPS) from somatic cells [21,22]. Because epigenetic events are dynamic and may be established in the absence of cell division, they can give rise to functional advantages that can be preferentially selected at much higher rates than somatic mutations and as such, are often early events in disease development [23,24]. There are a multitude of large-scale coordinated efforts to catalogue DNA cytosine methylation patterns and histone marks in the human epigenome [25], with additional efforts focused on the cancer epigenome [26].

In addition to DNA methylation marks, much of the functionality of the genome is dictated by the secondary structure of chromatin. At the smallest scale, the cell's genome is made up of two meters of helical DNA approximately 2 nm in width [27,28]. Helical DNA is further compacted by being wrapped in 1.65 superhelical turns around histone octamers forming a 10 nm fibre, resembling “beads-on-a-string” [29,30]. Histone tails throughout the genome are subject to post-translational modifications, most commonly: acetylation, methylation, phosphorylation and ubiquitylation. These modifications serve as binding sites for effector proteins, which read, write and erase histone marks and alter the degree of chromatin compaction accordingly [31]. In this way, the “histone code”—defined by combinations of distinct histone tail modifications—regulates dynamic transitions between transcriptionally active and silent chromatin states [32].

Aging is characterized by a gradual loss of tissue function, physiological integrity, reduced fidelity of cellular processes and functions, such as DNA repair, and ultimately an increased susceptibility to cell death. Disruptions of epigenetic processes are risk factors in several age-related human pathologies such as Hutchinson-Gilford Progeria Syndrome (HGPS), Alzheimer’s disease (AD), Rheumatoid Arthritis (RA), Type-2 diabetes (TD2) and cancer. Aging research has experienced an explosive growth over recent years and many of the hallmarks of aging are now being elucidated (reviewed in [33]); however, a greater understanding of the epigenetic pathways contributing to age-related disease and the control of the rate of aging is needed. Here, we review the current state of knowledge of how the epigenome changes with age, and therefore may be involved in age-related diseases, and we further summarize plausible mechanisms mediating methylation drift.

Epigenetic Changes in the Aging Cell

At the whole genome level, aging is associated with a global loss of DNA methylation [34-36] and a concurrent, site-specific, increase in DNA methylation [37-40]. The positive correlation between increased methylation of CpG islands and shores with age was confirmed by a recent MWAS (methylome-wide association study) conducted on blood DNA from 718 men and women ranging in age from 25–72 [41]. In this study age-related methylation changes mapped to multiple genes, including: protocadherin genes (implicated in neural circuit development), homeobox genes (associated with aging and cellular senescence), ryanoide receptor genes (linked with aging and senescence) and mitogen-activated protein kinase genes (involved in regulating senescence) [41]. To define intra-individual methylation changes associated with aging, a longitudinal study compared global DNA methylation patterns of blood sampled from the 126 subjects, 16 years apart and found time-dependent marks of aging, including among others, Absent In Melanoma 1 (AIM1) and Colony-Stimulating Factor 3 Receptor (CSF3R) [42]. Interestingly, AIM1 is an immunological mediator promoting the release of pro-inflammatory cytokines in senescent cells that contribute to age-associated inflammatory diseases [43,44].

Changes to the epigenome are thought to contribute to the physiological, and even behavioural, changes that arise through the process of aging [45]. A classic system in which to study the role of non-genetic factors in aging are monozygotic twins (MZ). A study by Manel Esteller’s group showed that MZ twins, though they share virtually identical DNA sequences, display significant epigenetic differences that could account for phenotypic discordance between them [46]. The epigenomes of young MZ twins are very similar but patterns of methylation in MZ pairs diverge as they age. Epigenetics represents the crucial link between the genome and the environment; thus, epigenetically distinct landscapes in older twins can be explained, in part, by exposure to different environmental factors. Lifestyle choices, such as smoking habits, physical activity and diet, all contribute to the formation of age-accumulated epigenetic layers that modulate patterns of gene expression [46]. Further, it was shown that MZ twins who had spent more time apart had significantly different epigenomes and comitent gene expression profiles than MZ twins who had lived together and shared a similar environment [46,47]. Indeed, epigenomic analysis of a rare pair of MZ twins discordant for Alzheimer’s disease (AD) revealed substantial differences in DNA methylation in the temporal neocortex [48].

Clearly the phenotype of an organism is dependent upon both genetic and environmental variance; however, there is a noteworthy third factor that contributes to phenotypic discordance and that is biological stochasticity. A study performed in clonal crayfish found that there was significant developmental variability of the crayfish, at all life stages, despite having identical genomes and being raised in the same environment [49]. Therefore, contributions to epigenetic and phenotypic variability may also arise from a combination of genetic, environmental, and ill-defined “stochastic” factors [37].

Another epigenetic layer of the histone code is also known to have a distinctive profile in aging and in cancer. Generally, open or euchromatic chromatin structures are associated with acetylation of histone tail residues and de-acetylation of these residues are associated with closed or heterochromatin chromatin states; however, the establishment of a combinatorial pattern of multiple types of histone post-translational modifications ultimately directs chromatin compaction and guides gene expression. It has been well documented...
that modulation of the histone code has profound effects on a multitude of nuclear processes, such as DNA damage repair, heterochromatin maintenance, gene expression and telomere attrition, which are linked with aging. For example, the histone mark H4K20me3 (i.e., tri methylation of the lysine (K) that is the 20th amino acid on histone 4) is prevalent in differentiated tissues [50] and is known to increase with age [51]. Further, independent studies corroborate that methylation of H4K20 increases progressively with age in murine models and the abundance of this mark is positively associated with senescence [38,51]. While histone modification maps are likely relevant to aging phenotypes, exactly how changes in patterns of histone modifications contribute to the pathophysiology of aging remains to be elucidated.

Epigenetic defects acquired throughout life are believed to affect the behaviour of adult tissue-specific stem cells [52]. The declining function of these somatic stem cells, a process known as stem cell exhaustion, contributes to reduction in repair capacity, tissue homeostasis and loss of physiological integrity [33]. This attrition of stem cell activity can arise due to age-related accrual of genetic lesions (reviewed in [53]) and epigenetic alterations (reviewed in [52]). Studies in murine models show that nascent haematopoietic stem cells (HSCs) undergo asymmetric cell division more frequently than aged HSCs [54]. Although the number of stem cells does not necessarily decrease with age, their functional regenerative capacity (ability to make more progenitors) diminishes, leading to a loss of proliferative potential and tissue reconstitution [54]. Thus, older individuals, whose stem cells have undergone successive rounds of DNA replication and have been subjected to a greater degree of genetic and epigenetic instability, are more prone to stem cell exhaustion, loss of tissue homeostasis (one of the hallmarks of aging) and development of age-related disease, such as cancer [53,55]. Some have hypothesized that the secrets of youthfulness and age are inextricably linked to the epigenetic states of adult stem cells and their capacity for quiescence and self-renewal (reviewed in [56]).

Epigenetic Changes in Age-related Diseases

Since epigenetic systems normally modulate profound expression and phenotypic changes throughout a cell’s life, it follows that dysregulation of epigenetic patterns, as observed with aging, may contribute to age-related disease. The information contained in the epigenetic state of DNA and chromatin influences the expression of well-documented oncogenes, such as cMYC, TERT (regulators of proliferation and replicative immortality), and tumour suppressor genes, such as P53 and RB1 (regulators of senescence, among other features) [57]. Abnormal expression patterns of oncogenes and tumour suppressor genes have profound effects on the initiation and development of many cancer types [58]. Interestingly, many of the epigenetic alterations and chromatin changes that are hallmarks of aging [33], are also closely linked to cancer susceptibility and tumorigenesis [58-60]. For example, in cancer, DNA hypomethylation occurs globally frequently at repetitive DNA elements, which is thought to contribute to increased chromosomal instability [61,62] and the activation of transposons [63] (Figure 1B). Further, in malignant cells, tumor-type-specific transcriptional silencing of tumour suppressor genes (TSGs) is strongly correlated with hypermethylation of their associated promoters [64-76]. The same trend—widespread DNA hypomethylation and focal CpG island hypermethylation—is also observed in epigenome of human senescent cells [57]. Hypomethylation of interspersed repetitive sequences, such as Long Interspersed Elements (LINEs), Short Interspersed Elements (SINEs) and LTR retrotransposons, occurs progressively with age and is linked to a decline in organ function [77-81]. Additionally, an age-dependant hypermethylation signature can be seen in the promoter regions of genes normally targeted by Polycomb Group (PcG) proteins, which are proteins involved in transcriptional silencing [82]. Interestingly, this age-PcG target methylation profile can be used to distinguish normal cells from pre-invasive cancer cells [82]. Methylation changes associated with aging have also been observed in the transformation of a normal cell into a cancer cell (reviewed in [35]), thus some have suggested these changes may contribute to the increased risk for cancer with age [59].

One disease that might reveal clues about the physiological mechanisms of aging is Hutchinson-Gilford Progeria Syndrome (HGPS)—a rare disorder causing affected individuals to age at ten times the normal rate [83]. Patients with HGPS usually manifest symptoms of aging, such as limited growth, hair loss, wrinkled skin and lipodystrophy, at a very early age [83-86], and typically die from cardiovascular disease or atherosclerosis at around 13 years of age [83]. Progeria is caused by a mutation in the LMNA gene, encoding for nuclear lamina, which is present on the inner side of the nuclear membrane (reviewed in [87]). Nuclear lamin are fibrous proteins which form a highly dynamic meshwork between the inner nuclear membrane and chromatin [88]. Mutations or aberrant splicing of lamin-A, called progerin, that becomes constitutively farnesylated and anchored in the nuclear membrane [86]. Progerin accumulates gradually as a physiological consequence of normal aging; however, in HGPS patients, progerin agglomerates at an accelerated rate. Increased levels of nuclear progerin have been linked to many age-related phenotypes including: telomeric aberrations, defective DNA repair, mitochondrial dysfunction, altered cell cycle regulation and cellular senescence [86,89,90]. Interestingly, the epigenetic architecture of HGPS mimics the epigenetics of normal aging [86].

Nuclear lamins play a crucial role in higher order chromatin organization and the regulation of gene expression (reviewed in [91]). Recently, it has been shown that epigenetic modifications known to regulate the dynamics of chromatin organization might be involved in the underlying physiology of HGPS [86,92,93]. In HGPS cells, the
non-random arrangement of chromosomes into discrete territories is perturbed due to the presence of abundant progerin. The consequences of such distortion are a loss of peripheral heterochromatin, rampant nuclear disorganization and nuclear lobulation or blebbing [89,94]. Of note, several proteins involved in maintaining nuclear architecture, such as barrier-to-autointegration factor (BAF) [95], inhibitor of growth protein 1 (ING1) [96] and D4Z4 [97], are also frequently lost in progeroid cells. In addition to aberrations in nuclear architecture, HGPS patients display a substantial down regulation of the histone variant γH2AX, an important marker of DNA repair. This down regulation of γH2AX likely contributes to the accumulation and persistence of DNA damage in HGPS cells [98]. As is the case with cellular senescence, fibroblasts from individuals with HGPS display a loss of two histone marks associated inactive chromatin, H3K27me3 and H3K9me3 [93,99,100]. In support of these findings, it has been shown that pericentric regions (genomic regions normally embedded in silent chromatin) are transcriptionally upregulated in HGPS cells that lose H3K27me3 [99]. In addition to loss of H3K27me3 and H3K9me3, loss of H4K16 acetylation, a mark important in the DNA damage response, has also been reported in an animal model of this disease [101]. Interestingly, treatment of mice with sodium butyrate, a compound that inhibits histone deacetylase enzymes, revived levels of H4K16 acetylation and rescued mice from the progeroid phenotype [101].

Other non-oncogenic diseases, such as Alzheimer’s disease (AD), are strongly associated with aging and can also be linked to specific epigenetic alterations [102,103]. AD is a progressive neurodegenerative disorder that can occur in old age and is often characterized by accumulation of amyloid β peptides and abnormally phosphorylated tau proteins [104,105]. The altered methylation state of the AD brain typically results in gene expression alterations in two primary pathogenetic pathways: amyloid precursor protein (APP) processing and tau hyper phosphorylation [102,106]. For example, one study found that glioblastoma cells which express 2.6-fold higher levels of APP display a global reduction DNA methylation and this hypomethylation resulted in the ectopic expression of several AD-associated genes such as PS1, BACE1 and APP itself [107]. In the rat model of AD, increased H3 acetylation and decreased promoter methylation in the region of cyclin dependent kinase 5 (cdk5), lead to increased hippocampal cdk5 activity, tau phosphorylation, synaptic dysfunction and memory loss [104].

It has been shown that DNA methylation in the forebrain, which is maintained by Dnmt1 and Dnmt3a, is intrinsically involved in regulating synaptic function and memory formation [108-110] Indeed, both aging and cognitive impairment are associated with global DNA hypomethylation and widespread down regulation of Dnmt1 and Dnmt3a in the hippocampus [111,112]. This finding is exacerbated in individuals with AD [113-115]. Thus, aging-associated defects in hippocampal DNA methylation might underlie the spatial memory deficits characteristic of AD. Interestingly, a genome-wide brain DNA methylation study found that many differentially methylated genes identified in late-stage AD brains also occurred in presumptive AD brains, raising the possibility that these DNA methylation alterations may be an early feature of AD pathology. Early DNA methylation alterations at ankyrin 1 (ANK1), disco-interacting protein 2 (DIP2A), rhomboid family member 2 (RHBDF2), ribosomal protein L13 (RPL13), SERPINF1 and SERPINF2 are connected to a network of known AD susceptibility genes and may have a role in the onset of AD [116]. In another study, two genes, SORBS3, involved in cell adhesion, and S100A2, a calcium binding protein, have been found to become progressively more methylated with age and their methylation becomes accelerated in patients with AD [95]. However, not all genes implicated in AD pathogenesis are associated with age-related changes in DNA methylation. One gene involved in β-amyloid post-translational processing, TME5M9, is hypermethylated in AD patients but remains relatively unaffected in elderly controls [117]. Additionally, in other age-related diseases, such as rheumatoid arthritis (RA) and type 2 diabetes (TD2), methylation changes have been implicated— an MWAS identified characteristic methylome signatures in RA [118,119] and work by Ronn et al. showed that age-related promoter hypermethylation of COX7A1, a gene important for glucose metabolism, might contribute to the onset of TD2 [120].

**Mechanism of Age-related Methylation Drift**

Since epigenetics is the interface between environmental agents and genomic programming, it follows that the accumulation of environmental damage correlates with epigenetic dysregulation and with the pathogenesis of age-related disease [121]. One mechanism of epigenetic dysregulation occurs through methylation drift—the stochastic change in DNA methylation patterns at certain loci, reflective of the imperfect maintenance of epigenetic machinery [55,66]. Considering the accuracy of DNA methyltransferase enzymes (95% for DNMT1), methylation patterns is bound to become inaccurate with numerous passages through the cell cycle (Figure 2A) [122-124].

![Figure 2](image)

**Figure 2:** (A) Mechanisms of epigenetic drift. External/endogenous factors such as ROS, inflammation, diet and other environmental stresses can cause lesions in epigenetic maintenance systems. Loss of fidelity of methylation transferase enzymes (left) or demethylation enzymes (right) leads to aberrant propagation of CpG methyl marks and methylation drift. Disruption of enzymes that modify the histone code (middle) can result in a rearranged chromatin secondary structure and subsequent aberrant CpG methylation. ROS: Reactive Oxygen Species; Dnmt1: DNA methyltransferase 1; Dnmt 3a/b: DNA methyltransferase 3a/b; HDAC: Histone Deacetylase; CRC: Chromatin Remodeling Complex; TET: Ten-Eleven Translocation Methylcytosine Dioxxygenases; HMT: Histone Methyltransferase.

Stochastic differential methylation patterns that arise in aging individuals create an epigenetic mosaicism that may allow for the selection of biological defects leading to cancer and other age-related diseases (Figure 2B) [2,55,66,125]. Generally, methylation drift (differential site specific hypo- or hypermethylation) occurs in all individuals past a certain age [41]; however, rates of methylation drift
vary depending on local transcriptional activity [126], the methylation state [127], histone tail modifications [128-130], polymorphisms in gene sequence [131-133] and activity of trans-acting factors such as DNMTs, TETs [134], DNMT3L [135], CTCF [136] and long-noncoding RNAs [137].

Figure 2: (B) Epigenetic changes may initiate cancer phenotypes by priming cells in such a way as to make them more susceptible to subsequent pathological genetic or epigenetic changes. Young stem cell populations, after successive rounds of replication and greater accrual of epigenetic drift, become a mosaic population of stem cells with epigenetically different landscapes. Continued replication and epigenetic drift leads to stem cell exhaustion and/or selection of cells with a proliferative advantage.

In addition to the dysregulation of enzymes that write the DNA methylome, a critical regulatory mechanism of methylation drift lies in the fidelity of enzymes that erase the methylome (Figure 2A). As previously mentioned, the recently discovered TET family of dioxygenases is believed to mediate the oxidation of 5mC thereby priming it for removal by the Base Excision Repair pathways (BER) [92]. Disruption of the epigenetic machinery responsible for active demethylation can lead to age-specific 5hmC profiles [138] and/or DNA demethylation profiles [139]. Interestingly, methylation drift is associated with promoter hypomethylation of PSEN1 and APOE genes important in the age-dependant onset of neurodegenerative diseases such as AD [139]. A major source of sequence mutations in the human genome is spontaneous deamination of methylated cytosines which occurs when methylated cytosines undergo hydrolysis and subsequent conversion into thymine, resulting in a T:G base pair mismatch [140]. This mismatch, leads to the general depletion of CpG dinucleotides from mammalian genomes [141] and the accumulation of sequence mutations which may be deleterious over time [142].

Chemical modifications to DNA are not isolated events, but occur as part of a complex chromatin network that is mediated by extensive cross talk between different post-translationally modified histone structures and proteins, thus disruption of any one of these components can lead to deleterious epigenomic effects [3,73,143-145]. One enzyme which modifies the histone code to regulate specific biological process is Sirtuin1 (SIRT1)—an NAD+-dependant, class III Histone Deacetylase (HDAC) that plays a role in senescence, aging and cancer development [146,147]. HDACs, such as Sirtuin4, can regulate gene expression by removing acetyl groups from lysine residues on histone tails causing chromatin to re-order into a more condensed transcriptionally inactive state [148]. Early studies of the sirtuin homologue, silent information regulator 2 (SIR2), in multiple organisms have shown that SIR2 can increase life span [149-151]. Over the past years, studies in mammals have shown that SIRT1 is expressed in most tissues and its expression is reduced in senescent cells [152] and during aging [153]. Caloric restriction [154], cellular stress [155-157] and polyphenols (such as resveratrol) [147] stimulate the activity of Sirt1, which leads to cell survival and longevity by increasing transcriptional silencing and genome stability, fat metabolism and stress resistance [158]. The oncogenic potential of Sirtuins stems from their role in controlling several central molecular pathways, many of which are directly involved in cancer. For example, Sirt1 directly deacetylates and inactivates TSGs such as p53 [159], HIC1 [160] and p73 [161], and is implicated in the dysregulation of energy homeostasis, the hypoxic response, the PI3K/AKT signaling pathway, TGF-β signaling, Wnt signaling and DNA damage repair (reviewed in [162]. At the chromatin level, upregulation of Sirt1 during tumorigenesis could lead to the establishment of a cancer-specific histone modification profile [144,163,164]. Consistent with the observation that Sirtuin proteins are tightly linked to cellular metabolic pathways [165], upregulation of Sirt1 in mice has been shown to ameliorate symptoms of a variety of age-related metabolic diseases including T2D, AD and cancer [166].

**Epigenetic Based Diagnostic and Therapeutic Strategies**

DNA methylation profiles are relatively malleable and are often early neoplastic events, thus the exploration of epigenetic marks as early detection, diagnostic and predictive biomarkers is an enormous field of study (reviewed in [60]). Moreover, in contrast to DNA sequence level alterations, epigenetic modifications are reversible. Epigenetic based drugs which reverse aberrant DNA methylation or histone profiles (albeit non-specifically) through the inhibition of DNMT or histone modifying enzymes (specifically histone deactylase inhibitors, HDACs) are approved chemotherapies for some diseases including TD2, AD and cancer [166].

Epigenetic Based Therapeutics will no doubt improve. Encouragingly, since an early detection, diagnostic and predictive biomarkers is an enormous field of study and epigenetic modifications are reversible. Epigenetic based drugs which reverse aberrant DNA methylation or histone profiles (albeit non-specifically) through the inhibition of DNMT or histone modifying enzymes (specifically histone deactylase inhibitors, HDACs) are approved chemotherapies for some malignancies. The assessment and development of epigenetic-based treatment strategies for a broad variety of cancer types is an active field of cancer research [167]. Since the epigenome can also be modulated by diet, prevention is an emerging field of research for malignant and non-malignant disease. For example, epigenetic modifications implicated in the pathogenesis of Alzheimer’s disease, such as genes involved in neural pathways for learning and memory are found to be hypomethylated in AD [168]; therefore, it is postulated that dietary supplementation with methyl donors (i.e. folate) may help restore cognitive performance that declines with age [169,170]. HDAC inhibitors have also been shown to have potential clinical relevance in AD; valproic acid, a pan-HDAC inhibitor, was shown to lead to a reduction in β-amyloid production and alleviate behavioural deficits in murine models of AD [171]. Currently, epigenetic-based drugs are non-specific; however, as knowledge about the mechanisms guiding specificity of epigenetic machinery emerges, the targeting of epigenetic based therapeutics will no doubt improve. Encouragingly, since an individual’s epigenome can be modulated by healthy dietary and lifestyle choices (e.g., increased intake of vegetables, quitting/not smoking); reduced risk of disease associated with these healthy choices may be in part modulated epigenetically.

**Conclusion**

It is clear that the biological pathways underlying age-related disease are associated with epigenetic dysregulation, however many questions remain unanswered regarding i) the precise mechanisms governing these processes, ii) timing and iii) interactions between an individual’s environment, epigenome and genome. With the advent of powerful new experimental pipelines built around high-throughput next generation sequencing, initiatives such as The Encyclopedia of DNA Elements (ENCODE) consortium [172,173] and The NIH
Roadmap Epigenomic Mapping Consortium, have undertaken large-scale coordinated efforts to catalogue DNA cytosine methylation patterns and histone marks in the human epigenome. In conclusion, a greater understanding of the epigenetic basis of age-associated disorders is needed to inform the development of exciting new therapeutic intervention and prevention strategies targeting these diseases. As the population of elderly individuals continue to grow, these questions become increasingly pertinent.

Acknowledgements

Funding support for this work is through research grants to W.L.L. from Canadian Institutes for Health Research (CIHR), Canadian Cancer Society, and Terry Fox Foundation. E.A.V. is supported by Charles Best Canada Graduate Scholarship from CIHR.

References

1. Holliday R (1987) The inheritance of epigenetic defects. Science 238: 163-170.
2. Maegawa S, Hinkal G, Kim HS, Shen L, Zhang L, et al. (2010) Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res 20: 332-340.
3. Bernstein BE, Meeßen A, Lander ES (2007) The mammalian epigenome. Cell 128: 669-681.
4. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, et al. (2009) The human colon cancer methyleome shows similar hypypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41: 178-186.
5. Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, et al. (2007) Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res 20: 332-340.
6. Wrobel K, Caruso JA (2009) Epigenetics: an important challenge for ICP-MS in metallomics studies. Anal Bioanal Chem 393: 481-486.
7. Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 484-492.
8. Morgan HD, Santos F, Green K, Dean W, Reik W (2005) Epigenetic reprogramming in mammals. Hum Mol Genet 14 Spec No 1: R47-58.
9. Ishii Y, Torres-Padilla ME (2013) Towards an understanding of the regulatory mechanisms of totipotency. Curr Opin Genet Dev 23: 512-518.
10. Seisenberger S, Peat JT, Hore TA, Santos F, Dean W, et al. (2013) Reprogramming DNA methylation in the mammalian life cycle: building and breaking epigenetic barriers. Philos Trans R Soc Lond B Biol Sci 368: 20110330.
11. Reik W (2007) Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447: 425-432.
12. Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257.
13. Miller CA, Sweett JD (2007) Covalent modification of DNA regulates memory formation. Neuron 53: 857-869.
14. Morris MJ, Adachi M, Na ES, Monteggia LM (2014) Selective role for Dnmt3a in learning and memory. Neurobiol Learn Mem.
15. Tahlilani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, et al. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930-935.
16. Ito S, Shen L, Dai Q, Wu SC, Collins LB, et al. (2011) Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333: 1300-1303.
17. Ji H, Ehrlich LI, Seita J, Murakami P, Doi A, et al. (2010) Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 467: 338-342.
18. Byun HM, Siegmund KD, Pan F, Weisenberger DJ, Kandel G, et al. (2009) Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns. Hum Mol Genet 18: 4808-4817.
19. Fraser HB, Lam LL, Neumann SM, Kobor MS (2012) Population-specificity of human DNA methylation. Genome Biol 13: R8.
20. Nishino K, Hattori N, Tanaka S, Shiota K (2004) DNA methylation-mediated control of Sry gene expression in mouse gonadal development. J Biol Chem 279: 22306-22313.
21. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, et al. (2009) Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 41: 1350-1353.
22. Kim K, Doi A, Wen B, Ng K, Zhao R, et al. (2010) Epigenetic memory in induced pluripotent stem cells. Nature 467: 285-290.
23. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128: 683-692.
24. Gal-Yam EN, Saito Y, Egger G, Jones PA (2008) Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 59: 267-280.
25. Jones PA, Martienssen R (2005) A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop. Cancer Res 65: 11241-11246.
26. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, et al. (2005) Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37: 853-862.
27. Anderson CW (1993) DNA damage and the DNA-activated protein kinase. Trends Biochem Sci 18: 433-437.
28. Mou J, Czajkowsky DM, Zhang Y, Shao Z (1995) High-resolution atomic-force microscopy of DNA: the pitch of the double helix. FEBS Lett 371: 279-282.
29. Fussner E, Ching RW, Bazett-Jones DP (2011) Living without 30nm chromatin fibers. Trends Biochem Sci 36: 1-6.
30. Misteli T (2007) Beyond the sequence: cellular organization of genome function. Cell 128: 787-800.
31. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293: 1074-1080.
32. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403: 41-45.
33. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153: 1194-1217.
34. Gonzalez S (2010) Epigenetic alterations in aging. J Appl Physiol (1985) 109: 586-597.
35. Calvenese V, Lara E, Kahn A, Fraga MF (2009) The role of epigenetics in aging and age-related diseases. Ageing Res Rev 8: 268-276.
36. Fuke C, Shimabukuro M, Petronia S, Sugimoto J, Oda T, et al. (2004) Age related changes in 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-based study. Ann Hum Genet 68: 196-204.
37. Fraga MF (2009) Genetic and epigenetic regulation of aging. Curr Opin Immunol 21: 446-453.
38. Fraga MF, Esteller M (2007) Epigenetics and aging: the targets and the marks. Trends Genet 23: 413-418.
39. Bell JT, Tsai PC, Yang TP, Pidwosky R, Nisbet J, et al. (2012) Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. PLoS Genet 8: e1002629.
40. Rakyan VK, Down TA, Masiuk D, Spear S, Yang TP, et al. (2010) Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin domains. Genome Res 20: 434-439.
41. McClay J, Aberg KA, Clark SL, Neriella S, Kumar G, et al. (2014) A methylome-wide study of aging using massively parallel sequencing of the methyl-CpG-enriched genomic fraction from blood in over 700 subjects. Hum Mol Genet 23: 1175-1185.

Citation: Rowbotham DA, Marshall EA, Vucic EA, Kennett JY, Lam WL, et al. (2014) Epigenetic Changes in Aging and Age-related Disease. JASC 3: 130. doi:10.4172/2329-8847.1000130
42. Bjornsson HT, Sigurdsson ML, Fallin MD, Irizarry RA, Aspelund T, et al. (2008) Intra-individual change over time in DNA methylation with familial clustering. JAMA 299: 2877-2883.

43. Duan X, Pononareva L, Veeranki S, Panchanathan R, Dickerson E, et al. (2011) Differential roles for the interferon-inducible IFI16 and AIME innate immune sensors for cytosolic DNA in cellular senescence of human fibroblasts. Mol Cancer Res 9: 589-602.

44. Thewissen M, Somers V, Venken K, Linsen L, van Paassen P, et al. (2007) Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol 123: 209-218.

45. Meaney MJ (2010) Epigenetics and the biological definition of gene x environment interactions. Child Dev 81: 41-79.

46. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, et al. (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 102: 10604-10609.

47. Sharma A, Sharma VK, Horn-Saban S, Lancet D, Ramachandran S, et al. (2005) Assessing natural variations in gene expression in humans by comparing with monozygotic twins using microarrays. Physiol Genomics 21: 117-123.

48. Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD (2009) Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One 4: e6617.

49. Vogt G, Huber M, Thiemann M, van den Boogaart G, Schmitz OJ, et al. (2008) Production of different phenotypes from the same genotype in the same environment by developmental variation. J Exp Biol 211: 510-523.

50. Biron VL, McMannus KJ, Hu N, Hendzel MJ, Underhill DA (2004) Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Dev Biol 276: 337-351.

51. Sarg B, Koutzamani E, Helliger W, Rundquist I, Lindner HH (2002) Posttranslational trimming of histone H4 at lysine 20 in mammalian tissues is associated with aging. J Biol Chem 277: 39195-39201.

52. Pollina EA, Brunet A (2011) Epigenetic regulation of aging stem cells. Oncogene 30: 3105-3126.

53. Sharpless NE, DePinho RA (2007) How stem cells with age. Nat Rev Mol Cell Biol 12: 555-566.

54. Sarg B, Koutzamani E, Helliger W, Rundquist I, Lindner HH (2002) Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Dev Biol 276: 337-351.

55. Issa JP (2014) Aging and epigenetic drift: a vicious cycle. J Clin Invest 124: 24-29.

56. Rando TA, Chang HY (2012) Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock. Cell 148: 46-57.

57. Cruickshanks HA, McManus KJ, Dandoo SA, Vanderkraats ND, Shah PP, et al. (2013) Senescent cells harbour features of the cancer epigenome. Nat Cell Biol 15: 1495-1506.

58. Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150: 12-27.

59. Zane I, Sharma V, Misteli T (2014) Common features of chromatin in aging and cancer: cause or coincidence? Trends Cell Biol .

60. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome — biological and translational implications. Nat Rev Cancer 11: 726-734.

61. Eden A, Gaudet F, Waghmare A, Jaenisch R (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455.

62. Karpf AR, Matsui S (2005) Genetic disruption of cytokine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res 65: 8635-8639.

63. Bestor TH (2005) Transposons reanimated in mice. Cell 122: 322-325.

64. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, et al. (2000) Abrerrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24: 132-138.

65. Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypomethylation profile of human cancer. Cancer Res 61: 3225-3229.

66. Maegawa S, Gough SM, Watanabe-Okochi N, Lu Y, Zhang N, et al. (2014) Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res 24: 580-591.

67. Arnold CN, Goel A, Niedzwiecki D, Dowell JM, Wasserman L, et al. (2004) APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on Sq. Cancer Biol Ther 3: 960-964.

68. Gregor V, Passarge E, Hopping W, Messmer E, Horsthemke B (1989) Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 83: 155-158.

69. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, et al. (1991) Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48: 880-888.

70. Herman JG, Latif F, Wang Y, Lerman LM, Zbar B, et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91: 9700-9704.

71. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. (1995) 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MST51 in human cancers. Nat Med 1: 686-692.

72. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, et al. (1995) Methylation of the 5’ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531-4535.

73. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.

74. Esteller M, Silva JM, Domínguez G, Bonilla F, Mattáz-Guiu X, et al. (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92: 564-569.

75. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, et al. (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443.

76. Lumbledo A, Ropero S, Ballestar E, Fraga MF, Cerrato C, et al. (2007) Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67: 1424-1429.

77. Jintaridith P, Mutirangura A (2010) Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. Physiol Genomics 41: 194-200.

78. Lange NE, Sordillo J, Tarantini L, Bollati V, Sparrow D, et al. (2012) Alu and LINE-1 methylation and lung function in the normative ageing study. BMJ Open 2.

79. Rodriguez J, Vives L, Jordá M, Morales C, Muñoz M, et al. (2008) Genome-wide tracking of unmethylated DNA Alu repeats in normal and cancer cells. Nucleic Acids Res 36: 770-784.

80. Christensen BC, Houserman EA, Marist JG, Zheng S, Wrensch MR, et al. (2009) Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 5: e1000602.

81. Heyn H, Li N, Ferreira HJ, Moran S, Pisano DG, et al. (2012) Alu and LINE-1 methylation and lung function in the normative ageing study. BMJ Open 2.

82. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, et al. (2010) Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 20: 440-446.

83. Pollex RL, Hegele RA (2004) Hutchinson-Gilford progeria syndrome. Clin Genet 66: 375-381.

84. Gordon LB, Rothman FG, López-Otín C, Misteli T (2014) Progeria: a paradigm for translational medicine. Cell 156: 400-407.

85. Brown WT (1992) Progeria: a human-disease model of accelerated aging. Science 255: 826-831.
87.  Todd A, Hediger F, Neumann FR, Gasser SM (2004) The function of nuclear architecture: a genetic approach. Annu Rev Genet 38: 305-345.

88.  Kumaran RI, Spector DL (2008) A genetic locus targeted to the nuclear periphery in living cells maintains its transcriptional competence. J Cell Biol 180: 51-65.

89.  Prokocimer M, Barkan R, Gruenbaum Y (2013) Hutchinson-Gilford progeria syndrome through the lens of transcription. Aging Cell 12: 533-543.

90.  Rivera-Torres, J (2013) Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labelling with amino acids in cell culture. J Proteomics 91: 466-477.

91.  Sexton T, Schober H, Fraser P, Gasser SM (2007) Gene regulation through nuclear organization. Nat Struct Mol Biol 14: 1049-1055.

92.  He YF, Li BZ, Li Z, Liu P, Wang Y, et al. (2011) Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333: 1303-1307.

93.  Scaffidi P, Misteli T (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11: 448-455.

94.  Kubben N, Adriaens M, Meuleman W, Younken JW, van Stenzel B, et al. (2012) Mapping of lamin A- and progerin-interacting genome regions. Chromosoma 121: 447-464.

95.  Capanni C, Cenni V, Haraguchi T, Squarzoni S, Schütcher S, et al. (2010) Lamin A precursor induces barrier-to-autointegration factor nuclear localization. Cell Cycle 9: 2600-2610.

96.  Han X, Feng X, Rattner JB, Smith H, Bose P, et al. (2008) Tethering by lamin A stabilizes and targets the ING1 tumour suppressor. Nat Cell Biol 10: 1333-1340.

97.  Ottaviani A, Schluth-Bolard C, Rival-Gervil S, Boussouar A, Rondier D, et al. (2009) Identification of a perinuclear positioning element in human subtelomeres that requires A-type laminas and CTCF. EMBO J 28: 2428-2436.

98.  Hutchison CJ (2011) The role of DNA damage in laminopathy progeroid syndromes. Biochim Soc Trans 39: 1715-1718.

99.  Shumaker DK, Dechat T, Kohliamaer A, Adam SA, Bozovsky MR, et al. (2006) Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc Natl Acad Sci U S A 103: 8703-8708.

100. Scaffidi P, Misteli T (2006) Lamin A-dependent nuclear defects in human aging. Science 312: 1059-1063.

101. Krishnan V, Chow MZ, Wang Z, Zhang L, Liu B, et al. (2011) Histone H4 lysine 16 hypoacetylation is associated with defective DNA repair and premature senescence in Zmpste24-deficient mice. Proc Natl Acad Sci U S A 108: 12225-12330.

102. Bennett DA, Yu L, Yang J, Srivastava GP, Aupin C, et al. (2014) Epigenomics of Alzheimer's disease. Transl Res.

103. Wood H (2014) Alzheimer disease: AD-susceptible brain regions exhibit altered DNA methylation. Nat Rev Neurol 10: 548.

104. Li L, Zhang C, Zi X, Tu Q, Guo K (2014) Epigenetic modulation of Cd5k contributes to memory deficiency induced by amyloid fibrils. Exp Brain Res.

105. Wang Y, Yang R, Gu J, Yin X, Jin N, et al. (2014) Cross talk between P30-KRT-GSK3β and PP2A pathways determines tau hyperphosphorylation. Neurobiol Aging.

106. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, et al. (2008) Altered neuronal gene expression in brain regions differently affected by Alzheimer's disease: a reference data set. Physiol Genomics 33: 240-256.

107. Sung HY, Choi EN, Ahn Jo S, Oh S, Ahn JH (2011) Amyloid protein-mediated differential DNA methylation status regulates gene expression in Alzheimer's disease model cell line. Biochem Biophys Res Commun 414: 780-795.

108. Day JJ, Childs D, Guzman-Karlsson MC, Kibe M, Moulden J, et al. (2013) DNA methylation regulates associative reward learning. Nat Neurosci 16: 1445-1452.

109. Feng J, Zhou Y, Campbell SL, Le T, Li E, et al. (2010) Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat Neurosci 13: 423-430.

110. Miller CA, Gavin CF, White JA, Parrish RR, Honasoge A, et al. (2010) Cortical DNA methylation maintains remote memory. Nat Neurosci 13: 664-666.

111. Oliveira AM, Hemstedt TJ, Bading H (2012) Rescue of aging-associated decline in Dnmt3a2 expression restores cognitive abilities. Nat Neurosci 15: 1111-1113.

112. Su SC, Tsai LH (2012) DNA methylation in cognition comes of age. Nat Neurosci 15: 1061-1062.

113. Chouliaras L, Mastroeni D, Delvaux E, Grover A, Kenis G, et al. (2013) Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Neurobiol Aging 34: 2091-2099.

114. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, et al. (2010) Epigenetic changes in Alzheimer's disease: decrements in DNA methyltransferase activity. J Alzheimers Dis 22: 59-69.

115. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, et al. (2011) Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging 32: 1161-1180.

116. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, et al. (2014) Alzheimer's disease: early alterations in brain DNA methylation at ANKI1, BIN1, RHD/BF2 and other loci. Nat Neurosci 17: 1156-1163.

117. Bakulski KM, Dolinoy DC, Sarkor MA, Paulson HL, Konen JR, et al. (2012) Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis 29: 571-588.

118. Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hessler E, et al. (2013) Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 31: 142-147.

119. Nakano K, Whitaker JW, Boyle DL, Wang W, Firestone GS (2013) DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis 72: 110-117.

120. Rönn T, Poulsen P, Hansson O, Holmkvist J, Almgren P, et al. (2008) Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle. Diabetologia 51: 1159-1168.

121. Bredy TW, Sun YE, Kobor MS (2010) How the epigenome contributes to the development of psychiatric disorders. Dev Psychobiol 52: 331-342.

122. Goyal R, Reinhardt R, Jeltsch A (2006) Accuracy of DNA methylation pattern preservation by the Dnmt1 methyltransferase. Nucleic Acids Res 34: 1182-1188.

123. Yang G, Guo T (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21.

124. Yates PA, Burman R, Simpson J, Ponromoreva ON, Thayer MJ, et al. (2003) Silencing of mouse Aplt is a gradual process in differentiated cells. Mol Cell Biol 23: 4461-4470.

125. Zeki SS, Graham TA, Wright NA (2011) Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol 8: 90-100.

126. Takeshima H, Yamashita S, Shimazu T, Niwa T, Ushijima T (2009) The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res 19: 2025-2037.

127. Sharma S, De Carvalho DD, Jeong S, Jones PA, Liang G (2011) Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet 7: e1001286.

128. Ooi SK, Qiu C, Bernstein E, Li K, Jia D, et al. (2007) DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448: 714-717.

129. Otani J, Nankumo T, Arita K, Inamoto S, Ariyoshi M, et al. (2009) Structural basis for recognition of H3K4 methylation status by the DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain. EMBO Rep 10: 1235-1241.
